Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Fudan University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05742438CT.gov Effects of Dexmedetomidine/Lidocaine/Intrathecal Morphine on Cancer Metastasis Biomarker After Colorectal Surgery | — | Completed | — | — | — |
NCT05250791CT.gov Feasibility Study of Lidocaine Infusion During Bowel Cancer Surgery for Cancer Outcome | — | Unknown | — | — | — |
NCT05412576CT.gov a Pilot Study of Lidocaine Infusion for Postoperative Analgesia in Elderly Patients With Colorectal Cancer Surgery | — | Completed | — | — | — |
NCT04316013CT.gov Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial | — | Terminated | — | — | — |
NCT03462836CT.gov The Effects of Optimizing Post-operative Pain Management With Multi Modal Analgesia on Immune Suppression and Oncologic Outcome in Patients Undergoing Laparoscopic Colorectal Surgery | — | Withdrawn | — | — | — |
NCT04162535CT.gov Elucidation of the Mechanisms and Effects of Certain Anesthetic Interventions on Digestive Cancer Patients Subjected to Surgery | — | Unknown | — | — | — |
NCT02786329CT.gov Anesthesia and Postoperative Outcome in Colorectal Cancer Patients | — | Unknown | — | — | — |
NCT04017845CT.gov Screening for Colorectal Cancer in Average and High Risk Population | — | Completed | — | — | — |
NCT01841294CT.gov NK Activity Modulation Induced by Intravenous Lidocaine During Colorectal Laparoscopic Surgery | — | Unknown | — | — | — |
NCT00229567CT.gov Intra-op Lidocaine and Ketamine Effect on Postoperative Bowel Function | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lidocaine (this asset) | Fudan University | Approved | B · 62 |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Marble Dust | James Varani | P2/3 | BB |
| Oxaliplatin | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | P4 | BB |
| Orectalip | Sinphar Pharmaceutical Co., Ltd | P4 | BB |
| Fluorouracilum | UNICANCER | P4 | BB |
| Levofolinic Acid | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BB |
| Fentanyl | Mansoura University | P4 | BB |
| Panitumumab | MSPU des 3 Provinces | P3 | BB |
+42 more in the Colorectal Cancer cohort
Other indications for Lidocaine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Peripheral Neuropathy | — | P4 | BBB · 79 |
| Postherpetic Neuralgia | — | P4 | BBB · 78 |
| Post-Operative Pain, Non-Human Animal | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lidocaine in Colorectal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lidocaine-colorectal-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →